Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia

Stopped early · Phase 4

Conditions studied: Postherpetic Neuralgia

In brief

The primary objective is to explore whether sensory symptom cluster analysis is useful for predicting treatment response in Postherpetic Neuralgia.

Key facts

Study ID

NCT01603394

Run by

Pfizer

People needed

9

Starts

2012-10-01

Expected to finish

2013-06-01

Last updated by the study team

2014-07-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must have pain present for more than 3 months after the healing of the herpes zoster skin rash.
• At screening (V1) and baseline (V2), subjects must have a score of >=4 on the Numeric Rating Scale for Pain (1 week recall period).
• At baseline (V2), at least 4 pain diaries must be completed satisfactorily within the last 7 days and the average pain score must be >=4.

You may not qualify if…

• Subjects having other severe pain that may confound assessment or self evaluation of the pain due to PHN.
• Neurolytic or neurosurgical therapy for Postherpetic Neuralgia
• Skin conditions in the affected dermatome that could alter sensation.

Where it is running

• Pfizer Investigational Site — Leesburg, Florida, United States
• Pfizer Investigational Site — Lexington, Kentucky, United States
• Pfizer Investigational Site — Raleigh, North Carolina, United States
• Pfizer Investigational Site — Jekintown, Pennsylvania, United States
• Pfizer Investigational Site — Senftenberg, A-3541, Austria
• Pfizer Investigational Site — Vienna, Austria
• Pfizer Investigational Site — Schwerin, Germany
• Pfizer Investigational Site — Pretoria, Gauteng, South Africa
• Pfizer Investigational Site — Paarl, Western Cape, South Africa

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.